2024 JP Morgan Healthcare Conference
BRUKER - AN EMERGING LEADER OF THE POST-GENOMIC ERA
Bruker Cellular Analysis:
Beacon® Accelerates Discovery of Antibodies and of Cell-Based Cancer Therapies
Leveraging the unique Beacon (former Berkeley Lights) platform:
Development of T cell receptor T cell (TCR-T) and chimeric antigen receptor T cell
(CAR-T) therapies against novel cancer antigens
High-throughput cell-based CAR-T cell workflow tests capacity of CAR constructs
▪ Integration of multimodal data to predict CAR-T cell function and clinical efficacy
▪ Streamlining translation of cell-based therapies to the clinic
■
■
© 2023 Bruker
FINOMS
BRUKER
Utilizing immunogenomic
approaches to prioritize
targetable neoantigens
for personalized
cancer immunotherapy
Dr. Zamora and publication in
Frontiers of Immunology in Dec. 2023
Innovation with Integrity |
"... single cell platform, such as the Beacon, can link phenotypic, functional, and transcriptomic profiles of
neoantigen-reactive T cells to expedite translation of cell-based therapies to the clinic"
- Anthony Zamora, Assistant Professor, Medicine (Hematology and Oncology)
and Microbiology and Immunology, Medical College of Wisconsin
January 8, 2024
1
21View entire presentation